Company Overview
Snapshot
Founded in June 2011 by Haim Gil-ad, Fore Biotherapeutics operates with 51–200 employees. The company has raised $153.5M across 7 funding rounds from 14 investors. In August 2023, Fore Biotherapeutics announced a Series D financing round led by Medicxi.
Business overview
Fore Biotherapeutics is a precision oncology company that leverages functional genomics to develop treatments for patients with rare cancers. The company's core technology, called Foresight, elucidates disease biology to deliver hyper-targeted treatments for unaddressed tumor mutations. By retesting newly identified driver mutations against various compounds, Foresight identifies potential drug candidates that reduce oncogenic signaling pathway activity. Fore Biotherapeutics aims to provide personalized therapeutic solutions, serving the pharmaceuticals and healthcare sectors, specifically targeting patients with limited treatment options.
Strategic signal
In February 2023, Fore Biotherapeutics announced the first patient had been dosed in a global Phase 2 trial evaluating FORE8394 for BRAF-mutated solid and brain tumors. This milestone signals significant progress in the clinical development of their lead candidate, validating their precision oncology approach and indicating a potential future treatment option for patients with specific cancer mutations.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent funding event for Fore Biotherapeutics?
- In August 2023, Fore Biotherapeutics announced a Series D financing round. The round was led by Medicxi and SR One.
- What is the status of the clinical trial for FORE8394?
- In February 2023, Fore Biotherapeutics announced that the first patient had been dosed in a global Phase 2 trial evaluating FORE8394 for BRAF-mutated solid and brain tumors.
- Has Fore Biotherapeutics received any special designations for its drug candidates?
- In March 2023, Fore Biotherapeutics received FDA Orphan Drug Designation for FORE8394 for the treatment of primary brain and CNS malignancies. Additionally, in September 2022, the FDA granted Fast Track Designation to FORE8394 for the treatment of cancers harboring BRAF Class 1 and Class 2 Alterations.
- When did NovellusDx rebrand to Fore Biotherapeutics?
- In February 2021, NovellusDx established Fore Biotherapeutics U.S. as its operating company in the United States and rebranded, appointing Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer.
- What was the outcome of the proposed merger between Cancer Genetics and NovellusDx?
- In October 2019, Cancer Genetics settled a failed merger deal with NovellusDx, with NovellusDx receiving $6M from Interpace.